Dec 10, 2009 0
Neurologix Completes All Surgical Procedures In Its Clinical Trial For Parkinson’s Disease
Neurologix, Inc.
The top rated carbon reduction products
 |
Earth 4 Energy
This great site shows you how to cut your power bills by generating & |
|
 |
Green DIY Energy
This is an amazing product that will save you money and help the |
|
 |
Home Made Energy
If you've ever wanted to stop spending money on your electricity |
|
 |
Magniwork
This site promises the secrets of generating free electricity |
|
 |
Power 4 Home
A practical, easy to follow, step by step guide to generating |
Dec 8, 2009 0
Initiation Of CYT107 Study In HBV Expands Company’s Hepatitis Investigations, Which Include Three Ongoing Studies In Hepatitis C (HCV)
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in its Phase I/IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in combination with standard antiviral treatment and vaccination in HBeAg-negative chronic hepatitis B-infected (HBV) patients…
Dec 8, 2009 0
Biogen Idec’s Oral Compound BG-12 Achieves Development Milestones In MS And RA
Biogen Idec (NASDAQ: BIIB) today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA). In recent months, the last patient was enrolled in the CONFIRM trial, the second of two Phase III trials designed to evaluate the efficacy and safety of BG-12 as a monotherapy in patients with relapsing-remitting multiple sclerosis (RRMS)…
Dec 8, 2009 0
PharmAthene Presents Phase I Clinical Trial Results And New Therapeutic Animal Model Data For Protexia(R)
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced Phase I clinical trial results for Protexia®, a pegylated recombinant version of human butyrylcholinesterase (rBChE), which has been shown to be effective in animal models in preventing toxicity from exposure to chemical nerve agents…
Dec 8, 2009 0
Carfilzomib Demonstrates Encouraging Response Rates In Patients With Relapsed And/or Refractory Multiple Myeloma In An Ongoing Phase 2 Study
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced results from an ongoing Phase 2 study, known as the 004 study, of the company’s lead proteasome inhibitor, carfilzomib.
Loading ...